Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of LY900014 Test vs Reference Formulations in Healthy Subjects
NCT02752087Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2016
- Primary completion
- May 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of insulin lispro in diabetes mellitus (DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Insulin Lispro Area Under the Concentration Curve From Time Zero to 8 Hours. Started Apr 2016; status: completed.
02
Drugs
insulin lispro
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT02752087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02752087.